Psoriatic onychodystrophy: Clinical course, diagnosis and therapeutic aspects

Abstract

Psoriatic onychodystrophy is observed in about 80% of patients with psoriasis. Psoriasis can affect two nail structures ― the matrix and the nail bed.

Involvement of the nail matrix in the pathological process can lead to the formation of leukonychia, thimble symptom, red spots in the area of the hole and destruction of the nail plate. On the other hand, the lesion of the nail bed is characterized by the formation of onycholysis, subcutaneous hyperkeratosis and subcutaneous hemorrhages.

Nail lesions in psoriasis are accompanied by functional disorders and aesthetic defects, and also indicate a severe course of psoriasis.

Treatment of psoriatic onychodystrophy includes topical medications, systemic therapy in cases accompanied by extensive skin lesions.

This article is an overview of the main clinical features, diagnostic issues and evaluation methods, as well as treatment options for nail psoriasis.

Keywords

psoriasis / psoriatic onychodystrophy / severity assessment / severity indices / PASI / mNAPSI / NAPSI / treatment

References

[1] liang Y, Sarkar K, Tsoi LC, Gudjonsson JE. Psoriasis: A mixed autoimmune and autoinflammatory disease. Curr Opin Immunol. 2017;(49):1–8. doi: 10.1016/j.coi.2017.07.007

[2] liang Y., Sarkar M.K., Tsoi L.C., Gudjonsson J.E. Psoriasis: A mixed autoimmune and autoinflammatory disease // Curr Opin Immunol. 2017. Vol. 49. Р. 1–8. doi: 10.1016/j.coi.2017.07.007

[3] Potekaev NN, Zhukova OV, Artemieva SI. Successful using of netakimab in treatment of psoriasis, accompanying by psoriatic onychodistrophy. Med Advice. 2020;(12):64–70. (In Russ). doi: 10.21518/2079-701X-2020-12-64-70

[4] Потекаев Н.Н., Жукова О.В., Артемьева С.И. Успешное применение препарата нетакимаб при лечении псориаза, сопровождающегося явлениями псориатической ониходистрофии // Медицинский совет. 2020. № 12. C. 64–70. doi: 10.21518/2079-701X-2020-12-64-70

[5] Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68(4):654–662. doi: 10.1016/j.jaad.2012.08.015

[6] Armstrong A.W., Harskamp C.T., Armstrong E.J. Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies // J Am Acad Dermatol. 2013. Vol. 68, N 4. Р. 654–662. doi: 10.1016/j.jaad.2012.08.015

[7] Kovaleva YS, Vedler AA, Subbotin EA, Gribova GV. Psoriatic onychodistrophy asa marker of psoriasis severity and comorbidity. Vestnik SurGU. Meditsina. 2020;(4):51–57. (In Russ). doi: 10.34822/2304-9448-2020-4-51-57

[8] Ковалева Ю.С., Ведлер А.А., Субботин Е.А., Грибова Г.В. Псориатическая ониходистрофия как маркер тяжести псориаза и сопутствующей коморбидности // Вестник СурГУ. Медицина. 2020. № 4. C. 51–57. doi: 10.34822/2304-9448-2020-4-51-57

[9] Baran R. The burden of nail psoriasis: An introduction. Dermatology. 2010;221(Suppl 1):1–5. doi: 10.1159/000316169

[10] Baran R. The burden of nail psoriasis: An introduction // Dermatology. 2010. Vol. 221, Suppl. 1. Р. 1–5. doi: 10.1159/000316169

[11] Tan ES, Chong WS, Tey HL. Nail psoriasis: A review. Am J Clin Dermatol. 2012;13(6):375–388. doi: 10.2165/11597000-000000000-00000

[12] Tan E.S., Chong W.S., Tey H.L. Nail psoriasis: A review // Am J Clin Dermatol. 2012. Vol. 13, N 6. Р. 375–388. doi: 10.2165/11597000-000000000-00000

[13] Platonova AV, Zhukov AS, Khairutdinov VR, Samtsov AV. Psoriatic onychodistrophy: Clinical features (part 1). Bulletin Dermatol Venereol. 2018;94(6):7–14. (In Russ). doi: 10.25208/0042-4609-2018-94-6-7-14

[14] Платонова А.В., Жуков А.С., Хайрутдинов В.Р., Самцов А.В. Псориатическая ониходистрофия: клинические проявления (часть 1) // Вестник дерматологии и венерологии. 2018. Т. 94, № 6. C. 7–14. doi: 10.25208/0042-4609-2018-94-6-7-14

[15] Platonova AV. Psoriaticheskaya onichodistrofiya: epidemiolgiya, kliniko-laboratornaya diagnostika, lechenie [dissertation abstract]. Saint Petersburg; 2022. 32 р. (In Russ).

[16] Платонова А.В. Псориатическая ониходистрофия: эпидемиология, клинико-лабораторная диагностика, лечение: Автореф. дис. … кандидат медицинских наук. Санкт-Петербург, 2022. 32 с.

[17] Sukolina OS. Assessment of the severity of nail damage in psoriasis using NAPSI. Russ J Skin Venereal Dis. 2007;(5):83–85. (In Russ).

[18] Суколина О.С. Оценка тяжести поражения ногтей при псориазе с использованием NAPSI // Российский журнал кожных и венерологических болезней. 2007. № 5. С. 83–85.

[19] Haneke E. Nail psoriasis: Clinical features, pathogenesis, differential diagnoses, and management. Psoriasis (Auckl). 2017;(7):51–63. doi: 10.2147/PTT.S126281

[20] Haneke E. Nail psoriasis: Clinical features, pathogenesis, differential diagnoses, and management // Psoriasis (Auckl). 2017. N 7. Р. 51–63. doi: 10.2147/PTT.S126281

[21] Brazzelli V, Carugno A, Alborghetti A, et al. Prevalence, severity and clinical features of psoriasis in fingernails and toenails in adult patients: Italian experience. J Eur Acad Dermatol Venereol. 2012;26(11):1354–1359. doi: 10.1111/j.1468-3083.2011.04289.x

[22] Brazzelli V., Carugno A., Alborghetti A., et al. Prevalence, severity and clinical features of psoriasis in fingernails and toenails in adult patients: Italian experience // J Eur Acad Dermatol Venereol. 2012. Vol. 26, N 11. Р. 1354–1359. doi: 10.1111/j.1468-3083.2011.04289.x

[23] Armesto S, Esteve A, Coto-Segura P, et al. [Nail psoriasis in individuals with psoriasis vulgaris: A study of 661 patients. (In Spanish)]. Actas Dermosifiliogr. 2011;102(5):365–372. doi: 10.1016/j.ad.2011.02.007

[24] Armesto S., Esteve A., Coto-Segura P., et al. [Nail psoriasis in individuals with psoriasis vulgaris: A study of 661 patients. (In Spanish)] // Actas Dermosifiliogr. 2011. Vol. 102, N 5. Р. 365–372. doi: 10.1016/j.ad.2011.02.007

[25] Augustin M, Reich K, Blome C, et al. Nail psoriasis in Germany: Epidemiology and burden of disease. Br J Dermatol. 2010;(163):580–585. doi: 10.1111/j.1365-2133.2010.09831.x

[26] Augustin M., Reich K., Blome C., et al. Nail psoriasis in Germany: Epidemiology and burden of disease // Br J Dermatol. 2010. N 163. Р. 580–585. doi: 10.1111/j.1365-2133.2010.09831.x

[27] Egeberg A, See K, Garrelts A, Burge R. Epidemiology of psoriasis in hard-to-treat body loca-tions: Data from the Danish skin cohort. BMC Dermatol. 2020;20(1):3. doi: 10.1186/s12895-020-00099-7

[28] Egeberg A., See K., Garrelts A., Burge R. Epidemiology of psoriasis in hard-to-treat body loca-tions: Data from the Danish skin cohort // BMC Dermatol. 2020. Vol. 20, N 1. Р. 3. doi: 10.1186/s12895-020-00099-7

[29] Prignano F, Rogai V, Cavallucci E, et al. Epidemiology of psoriasis and psoriatic arthritis in Italya systematic review. Curr Rheumatol Rep. 2018;20(7):43. doi: 10.1007/s11926-018-0753-1

[30] Prignano F., Rogai V., Cavallucci E., et al. Epidemiology of psoriasis and psoriatic arthritis in Italya systematic review // Curr Rheumatol Rep. 2018. Vol. 20, N 7. Р. 43. doi: 10.1007/s11926-018-0753-1

[31] Blome C, Costanzo A, Dauden E, et al. Patient-relevant needs and treatment goals in nail psoriasis. Qual Life Res. 2016;25(5):1179–1188. doi: 10.1007/s11136-015-1136-y

[32] Blome C., Costanzo A., Dauden E., et al. Patient-relevant needs and treatment goals in nail psoriasis // Qual Life Res. 2016. Vol. 25, N 5. Р. 1179–1188. doi: 10.1007/s11136-015-1136-y

[33] Van der Velden HM, Klaassen KM, van de Kerkhof PC, Pasch MC. The impact of fingernail psoriasis on patients’ health-related and disease-specific quality of life. Dermatol. 2014;229(2):76–82. doi: 10.1159/000360696

[34] Van der Velden H.M., Klaassen K.M., van de Kerkhof P.C., Pasch M.C. The impact of fingernail psoriasis on patients’ health-related and disease-specific quality of life // Dermatology. 2014. Vol. 229, N 2. Р. 76–82. doi: 10.1159/000360696

[35] Blome C, Augustin M, Klein TM. Nail psoriasis and quality-of-life measurement in clinical trials: Call for the use of nail-specific instruments. Am J Clin Dermatol. 2021;22(6):747–755. doi: 10.1007/s40257-021-00622-7

[36] Blome C., Augustin M., Klein T.M. Nail Psoriasis and quality-of-life measurement in clinical trials: Call for the use of nail-specific instruments // Am J Clin Dermatol. 2021. Vol. 22, N 6. Р. 747–755. doi: 10.1007/s40257-021-00622-7

[37] Schäfer I, Rustenbach SJ, Radtke M, et al. [Epidemiology of psoriasis in Germany: Analysis of secondary health insurance data. (In German)]. Gesund-Heitswesen. 2011;73(5):308–313. doi: 10.1055/s-0030-1252022

[38] Schäfer I., Rustenbach S.J., Radtke M., et al. [Epidemiology of psoriasis in Germany: Analysis of secondary health insurance data. (In German)] // Gesund-Heitswesen. 2011. Vol. 73, N 5. Р. 308–313. doi: 10.1055/s-0030-1252022

[39] Salomon J, Szepietowski JC, Proniewicz A. Psoriatic nails: A prospective clinical study. J Cutan Med Surg. 2003;7(4):317–21. doi: 10.1007/s10227-002-0143-0

[40] Salomon J., Szepietowski J.C., Proniewicz A. Psoriatic nails: A prospective clinical study // J Cutan Med Surg. 2003. Vol. 7, N 4. Р. 317–321. doi: 10.1007/s10227-002-0143-0

[41] De Jong EM, Seegers BA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: Results of a recent interview with 1,728 patients. Dermatol. 1996;193(4):300–303. doi: 10.1159/000246274

[42] De Jong E.M., Seegers B.A., Gulinck M.K., et al. Psoriasis of the nails associated with disability in a large number of patients: Results of a recent interview with 1,728 patients // Dermatology. 1996. Vol. 193, N 4. Р. 300–303. doi: 10.1159/000246274

[43] Gregoriou S, Kalogeromitros D, Kosionis N, et al. Treatment options for nail psoriasis. Expert Rev Dermatol. 2008;3(3):339–344. doi: 10.1586/17469872.3.3.339

[44] Gregoriou S., Kalogeromitros D., Kosionis N., et al. Treatment options for nail psoriasis // Expert Rev Dermatol. 2008. Vol. 3, N 3. Р. 339–344. doi: 10.1586/17469872.3.3.339

[45] Mrovits U, Makleidt O, Eike K. A modern view on the treatment of psoriasis with nail plate damage. Polyclinic. 2013;(2):100–105. (In Russ).

[46] Мровиц У., Макелейдт О., Эйке К. Современный взгляд на лечение псориаза с поражением ногтевых пластин // Поликлиника. 2013. № 2. С. 100–105.

[47] Schons KR, Beber AA, Beck Mde O, Monticielo OA. Nail involvement in adult patients with plaque-type psoriasis: Prevalence and clinical features. An Bras Dermatol. 2015;90(3):314–319. doi: 10.1590/abd1806-4841.20153736

[48] Schons K.R., Beber A.A., Beck Mde O., Monticielo O.A. Nail involvement in adult patients with plaque-type psoriasis: Prevalence and clinical features // An Bras Dermatol. 2015. Vol. 90, N 3. Р. 314–319. doi: 10.1590/abd1806-4841.20153736

[49] Klaassen KM, van de Kerkhof PC, Pasch MC. Nail Psoriasis, the unknown burden of disease. J Eur Acad Dermatol Venereol. 2014;28(12):1690–1695. doi: 10.1111/jdv.12368

[50] Klaassen K.M., van de Kerkhof P.C., Pasch M.C. Nail Psoriasis, the unknown burden of disease // J Eur Acad Dermatol Venereol. 2014. Vol. 28, N 12. Р. 1690–1695. doi: 10.1111/jdv.12368

[51] Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1–27. doi: 10.1016/j.jaad.2005.07.073

[52] Sasseville D., Vender R.B., Murphy F., Muhn C.Y. Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy // J Am Acad Dermatol. 2007. Vol. 57, N 1. Р. 1–27. doi: 10.1016/j.jaad.2005.07.073

[53] Sergeev YV, Sergeev AY. Onychomycoses: Mycological infections of the nails. Moscow: GEOTAR-Meditsyna; 1998. 38 р. (In Russ).

[54] Сергеев Ю.В. Сергеев А.Ю. Oнихомикозы ― грибковые инфекции ногтей. Москва: ГЭОТАР-Медицина, 1998. 38 с.

[55] Singh G. Nails in systemic disease. Indian J Dermatol Venereol Leprol. 2011;77(6):646–651. doi: 10.4103/0378-6323.86472

[56] Singh G. Nails in systemic disease // Indian J Dermatol Venereol Leprol. 2011. Vol. 77, N 6. Р. 646–651. doi: 10.4103/0378-6323.86472

[57] Gregoriou S, Argyriou G, Larios G, Rigopoulos D. Nail disorders and systemic disease: What the nails tell us. J Fam Pract. 2008;(57):509–514.

[58] Gregoriou S., Argyriou G., Larios G., Rigopoulos D. Nail disorders and systemic disease: What the nails tell us // J Fam Pract. 2008. N 57. Р. 509–514.

[59] Hanno R, Mathes BM, Krull EA. Longitudinal nail biopsy in evaluation of acquired nail dystrophies. J Am Acad Dermatol. 1986;14(5 Pt 1):803–809. doi: 10.1016/s0190-9622(86)70097-2

[60] Hanno R., Mathes B.M., Krull E.A. Longitudinal nail biopsy in evaluation of acquired nail dystrophies // J Am Acad Dermatol. 1986. Vol. 14, N 5, Pt. 1. Р. 803–809. doi: 10.1016/s0190-9622(86)70097-2

[61] Micali G, Lacarrubba F, Massimino D, Schwartz RA. Dermatoscopy: Alternative uses in daily clinical practice. J Am Acad Dermatol. 2011;64(6):1135–1146. doi: 10.1016/j.jaad.2010.03.010

[62] Micali G., Lacarrubba F., Massimino D., Schwartz R.A. Dermatoscopy: Alternative uses in daily clinical practice // J Am Acad Dermatol. 2011. Vol. 64, N 6. Р. 1135–1146. doi: 10.1016/j.jaad.2010.03.010

[63] Yadav TA, Khopkar US. Dermoscopy to detect signs of subclinical nail involvement in chronic plaque psoriasis: A study of 68 patients. Indian J Dermatol. 2015;60(3):272–275. doi: 10.4103/0019-5154.156377

[64] Yadav T.A., Khopkar U.S. Dermoscopy to detect signs of subclinical nail involvement in chronic plaque psoriasis: A study of 68 patients // Indian J Dermatol. 2015. Vol. 60, N 3. Р. 272–275. doi: 10.4103/0019-5154.156377

[65] Grover C, Jakhar D. Onychoscopy: A practical guide. Indian J Dermatol Venereol Leprol. 2017;83(5):536–549. doi: 10.4103/ijdvl.IJDVL_242_16

[66] Grover C., Jakhar D. Onychoscopy: A practical guide // Indian J Dermatol Venereol Leprol. 2017. Vol. 83, N 5. Р. 536–549. doi: 10.4103/ijdvl.IJDVL_242_16

[67] Staberg B, Gammeltoft M, Onsberg P. Onychomycosis in patients with psoriasis. Acta Derm Venereol. 1983;(63):436–438.

[68] Staberg B., Gammeltoft M., Onsberg P. Onychomycosis in patients with psoriasis // Acta Derm Venereol. 1983. N 63. Р. 436–438.

[69] Natarajan V, Nath AK, Thappa DM, et al. Coexistence of onychomycosis in psoriatic nails: A descriptive study. Indian J Dermatol Venereol Leprol. 2010;76(6):723. doi: 10.4103/0378-6323.72468

[70] Natarajan V., Nath A.K., Thappa D.M., et al. Coexistence of onychomycosis in psoriatic nails: A descriptive study // Indian J Dermatol Venereol Leprol. 2010. Vol. 76, N 6. Р. 723. doi: 10.4103/0378-6323.72468

[71] Szepietowski JC, Salomon J. Do fungi play a role in psoriatic nails? Mycoses. 2007;50(6):437–442. doi: 10.1111/j.1439-0507.2007.01405.x

[72] Szepietowski J.C., Salomon J. Do fungi play a role in psoriatic nails? // Mycoses. 2007. Vol. 50, N 6. Р. 437–442. doi: 10.1111/j.1439-0507.2007.01405.x

[73] Schwartz RA. Erythema dyschromicum perstans: The continuing enigma of Cinderella or ashy dermatosis. Int J Dermatol. 2004;43(3):230–232. doi: 10.1111/j.1365-4632.2004.02001.x

[74] Schwartz R.A. Erythema dyschromicum perstans: The continuing enigma of Cinderella or ashy dermatosis // Int J Dermatol. 2004. Vol. 43, N 3. Р. 230–232. doi: 10.1111/j.1365-4632.2004.02001.x

[75] Tschen JA, Tschen EA, McGavran MH. Erythema dyschromicum perstans. J Am Acad Dermatol. 1980;2(4):295–302. doi: 10.1016/s0190-9622(80)80041-7

[76] Tschen J.A., Tschen E.A., McGavran M.H. Erythema dyschromicum perstans // J Am Acad Dermatol. 1980. Vol. 2, N 4. Р. 295–302. doi: 10.1016/s0190-9622(80)80041-7

[77] Rich P, Scher RK. Nail psoriasis severity index: A useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49(2):206–212. doi: 10.1067/s0190-9622(03)00910-1

[78] Rich P., Scher R.K. Nail psoriasis severity index: A useful tool for evaluation of nail psoriasis // J Am Acad Dermatol. 2003. Vol. 49, N 2. Р. 206–212. doi: 10.1067/s0190-9622(03)00910-1

[79] Cassell SE, Bieber JD, Rich P, et al. The modified nail psoriasis severity index: Validation of an instrument to assess psoriatic nail involve-ment in patients with psoriatic arthritis. J Rheumatol. 2007;34(1):123–129.

[80] Cassell S.E., Bieber J.D., Rich P., et al. The modified nail psoriasis severity index: Validation of an instrument to assess psoriatic nail involve-ment in patients with psoriatic arthritis // J Rheumatol. 2007. Vol. 34, N 1. Р. 123–129.

[81] Parrish CA, Sobera JO, Elewski BE. Modification of the nail psoriasis severity index. J Am Acad Dermatol. 2005;53(4):745–746. doi: 10.1016/j.jaad.2004.11.044

[82] Parrish C.A., Sobera J.O., Elewski B.E. Modification of the nail psoriasis severity index // J Am Acad Dermatol. 2005. Vol. 53, N 4. Р. 745–746. doi: 10.1016/j.jaad.2004.11.044

[83] Rusk AM, Fleischer AB. In psoriasis treatment, greater improvement in skin severity predicts greater improvement in nail severity. J Dermatolog Treat. 2021;32(8):894–897. doi: 10.1080/09546634.2020.1720578

[84] Rusk A.M., Fleischer A.B. In psoriasis treatment, greater improvement in skin severity predicts greater improvement in nail severity // J Dermatolog Treat. 2021. Vol. 32, N 8. Р. 894–897. doi: 10.1080/09546634.2020.1720578

[85] De Jong EM, Menke HE, van Praag MC, van De Kerkhof PC. Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: A double-blind study. Dermatol. 1999;199(4):313–318. doi: 10.1159/000018281

[86] De Jong E.M., Menke H.E., van Praag M.C., van De Kerkhof P.C. Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: A double-blind study // Dermatology. 1999. Vol. 199, N 4. Р. 313–318. doi: 10.1159/000018281

[87] Jones SM, Armas JB, Cohen MG, et al. Psoriatic arthritis: Out-come of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol. 1994;33(9):834–839. doi: 10.1093/rheumatology/33.9.834

[88] Jones S.M., Armas J.B., Cohen M.G., et al. Psoriatic arthritis: Out-come of disease subsets and relationship of joint disease to nail and skin disease // Br J Rheumatol. 1994. Vol. 33, N 9. Р. 834–839. doi: 10.1093/rheumatology/33.9.834

[89] Ortonne JP, Baran R, Corvest M, et al. Development and validation of nail psoriasis quality of life scale (NPQ10). J Eur Acad Dermatol Venereol. 2010;24(1):22–27. doi: 10.1111/j.1468-3083.2009.03344.x

[90] Ortonne J.P., Baran R., Corvest M., et al. Development and validation of nail psoriasis quality of life scale (NPQ10) // J Eur Acad Dermatol Venereol. 2010. Vol. 24, N 1. Р. 22–27. doi: 10.1111/j.1468-3083.2009.03344.x

[91] Fredriksson T, Pettersson U. Severe psoriasis: Oral therapy with a new retinoid. Dermatologica. 1978;(157):238–244. doi: 10.1159/000250839

[92] Fredriksson T., Pettersson U. Severe psoriasis: Oral therapy with a new retinoid // Dermatologica. 1978. N 157. Р. 238–244. doi: 10.1159/000250839

[93] Augustin M, Blome C, Costanzo A, et al. Nail assessment in psoriasis and psoriatic arthritis (NAPPA): Development and validation of a tool for assessment of nail psoriasis outcomes. Br J Dermatol. 2014;(170):591–598. doi: 10.1111/bjd.12664

[94] Augustin M., Blome C., Costanzo A., et al. Nail assessment in psoriasis and psoriatic arthritis (NAPPA): Development and validation of a tool for assessment of nail psoriasis outcomes // Br J Dermatol. 2014. N 170. Р. 591–598. doi: 10.1111/bjd.12664

[95] Reich K, Sullivan J, Arenberger P, et al. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. Br J Dermatol. 2021;184(3):425–436. doi: 10.1111/bjd.19262

[96] Reich K., Sullivan J., Arenberger P., et al. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study // Br J Dermatol. 2021. Vol. 184, N 3. Р. 425–436. doi: 10.1111/bjd.19262

[97] Yin S, Njai R, Barker L, et al. Summarizing health-related quality of life (HRQOL): Development and testing of a one-factor model. Popul Health Metr. 2016;(14):22. doi: 10.1186/s12963-016-0091-3

[98] Yin S., Njai R., Barker L., et al. Summarizing health-related quality of life (HRQOL): Development and testing of a one-factor model // Popul Health Metr. 2016. N 14. Р. 22. doi: 10.1186/s12963-016-0091-3

[99] Prinsen CA, Mokkink LB, Bouter LM, et al. COSMIN guideline for systematic reviews of patient-reported outcome measures. Qual Life Res. 2018;27(5):1147–1157. doi: 10.1007/s11136-018-1798-3

[100] Prinsen C.A., Mokkink L.B., Bouter L.M., et al. COSMIN guideline for systematic reviews of patient-reported outcome measures // Qual Life Res. 2018. Vol. 27, N 5. P. 1147–1157. doi: 10.1007/s11136-018-1798-3

[101] Rigopoulos D, Rompoti N, Gregoriou S. Management of nail psoriasis. Dermatol Clin. 2021;39(2):211–220. doi: 10.1016/j.det.2020.12.014

[102] Rigopoulos D., Rompoti N., Gregoriou S. Management of nail psoriasis // Dermatol Clin. 2021. Vol. 39, N 2. Р. 211–220. doi: 10.1016/j.det.2020.12.014

[103] Bardazzi F, Starace M, Bruni F, et al. Nail psoriasis: An updated review and expert opinion on available treatments, including biologics. Acta Derm Venereol. 2019;99(6):516–523. doi: 10.2340/00015555-3098

[104] Bardazzi F., Starace M., Bruni F., et al. Nail psoriasis: An updated review and expert opinion on available treatments, including biologics // Acta Derm Venereol. 2019. Vol. 99, N 6. Р. 516–523. doi: 10.2340/00015555-3098

[105] Ricardo JW, Lipner SR. Nail psoriasis in older adults: Epidemiology, diagnosis, and topical therapy. Dermatol Clin. 2021;39(2):183–193. doi: 10.1016/j.det.2020.12.011

[106] Ricardo J.W., Lipner S.R. Nail psoriasis in older adults: Epidemiology, diagnosis, and topical therapy // Dermatol Clin. 2021. Vol. 39, N 2. Р. 183–193. doi: 10.1016/j.det.2020.12.011

[107] Treewittayapoom C, Singvahanont P, Chanprapaph K, Haneke E. The effect of different pulse durations in the treatment of nail psoriasis with 595-nm pulsed dye laser: A randomized, double-blind, intrapatient left-to-right study. J Am Acad Dermatol. 2012;66(5):807–812. doi: 10.1016/j.jaad.2011.12.015

[108] Treewittayapoom C., Singvahanont P., Chanprapaph K., Haneke E. The effect of different pulse durations in the treatment of nail psoriasis with 595-nm pulsed dye laser: A randomized, double-blind, intrapatient left-to-right study // J Am Acad Dermatol. 2012. Vol. 66, N 5. Р. 807–812. doi: 10.1016/j.jaad.2011.12.015

[109] Nakamura RC, Abreu LD, Duque-Estrada B, et al. Comparison of nail lacquer clobetasol efficacy at 0.05%, 1% and 8% in nail psoriasis treatment: Prospective, controlled and randomized pilot study. An Bras Dermatol. 2012;87(2):203–211. doi: 10.1590/s0365-05962012000200003

[110] Nakamura R.C., Abreu L.D., Duque-Estrada B., et al. Comparison of nail lacquer clobetasol efficacy at 0.05%, 1% and 8% in nail psoriasis treatment: Prospective, controlled and randomized pilot study // An Bras Dermatol. 2012. Vol. 87, N 2. Р. 203–211. doi: 10.1590/s0365-05962012000200003

[111] Fischer-Levancini C, Sánchez-Regaña M, Llambí F, et al. Nail psoriasis: Treatment with tazarotene 0.1% hydrophilic ointment. Actas Dermosifiliogr. 2012;103(8):725–728. doi: 10.1016/j.ad.2012.04.008

[112] Fischer-Levancini C., Sánchez-Regaña M., Llambí F., et al. Nail psoriasis: Treatment with tazarotene 0.1% hydrophilic ointment // Actas Dermosifiliogr. 2012. Vol. 103, N 8. Р. 725–728. doi: 10.1016/j.ad.2012.04.008

[113] De Simone C, Maiorino A. Tassone F, et al. Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open-label study. J Eur Acad Dermatol Venereol. 2012;27(8):1003–1006. doi: 10.1111/j.1468-3083.2012.04642.x

[114] De Simone C., Maiorino A., Tassone F., et al. Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open-label study // J Eur Acad Dermatol Venereol. 2012. Vol. 27, N 8. Р. 1003–1006. doi: 10.1111/j.1468-3083.2012.04642.x

[115] Tzung TY, Chen CY, Yang CY, et al. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol. 2008;88(3):279–280. doi: 10.2340/00015555-0401

[116] Tzung T.Y., Chen C.Y., Yang C.Y., et al. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis // Acta Derm Venereol. 2008. Vol. 88, N 3. Р. 279–280. doi: 10.2340/00015555-0401

[117] Sánchez Regaña M, Márquez Balbás G, Millet PU. Nail psoriasis: A combined treatment with 8% clobetasol nail lacquer and tacalcitol ointment. J Eur Acad Dermatol Venereol. 2008;22(8):963–969. doi: 10.1111/j.1468-3083.2008.02679.x

[118] Sánchez Regaña M., Márquez Balbás G., Millet P.U. Nail psoriasis: A combined treatment with 8% clobetasol nail lacquer and tacalcitol ointment // J Eur Acad Dermatol Venereol. 2008. Vol. 22, N 8. Р. 963–969. doi: 10.1111/j.1468-3083.2008.02679.x

[119] Rigopoulos D, Gregoriou S, Katsambas A. Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: A double-blind study. Acta Derm Venereol. 2007;87(2):167–168. doi: 10.2340/00015555-0195

[120] Rigopoulos D., Gregoriou S., Katsambas A. Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: A double-blind study // Acta Derm Venereol. 2007. Vol. 87, N 2. Р. 167–168. doi: 10.2340/00015555-0195

[121] Regaña MS, Ezquerra GM, Millet PU, Mateos FL. Treatment of nail psoriasis with 8% clobetasol nail lacquer: Positive experience in 10 patients. J Eur Acad Dermatol Venereol. 2005;19(5):573–577. doi: 10.1111/j.1468-3083.2005.01253.x

[122] Regaña M.S., Ezquerra G.M., Millet P.U., Mateos F.L. Treatment of nail psoriasis with 8% clobetasol nail lacquer: Positive experience in 10 patients // J Eur Acad Dermatol Venereol. 2005. Vol. 19, N 5. Р. 573–577. doi: 10.1111/j.1468-3083.2005.01253.x

[123] Cannavò SP, Guarneri F. Vaccaro M, et al. Treatment of psoriatic nails with topical cyclosporin: A prospective, randomized placebo-controlled study. Dermatology. 2003;206(2):153–153. doi: 10.1159/000068469

[124] Cannavò S.P., Guarneri F., Vaccaro M., et al. Treatment of psoriatic nails with topical cyclosporin: A prospective, randomized placebo-controlled study // Dermatology. 2003. Vol. 206, N 2. Р. 153–153. doi: 10.1159/000068469

[125] Bianchi L, Soda R, Diluvio L, Chimenti S. Tazarotene 0-1% gel for psoriasis of the fingernails and toenails: An open, prospective study. Br J Dermatol. 2003;149(1):207–209. doi: 10.1046/j.1365-2133.2003.05392.x

[126] Bianchi L., Soda R., Diluvio L., Chimenti S. Tazarotene 0-1% gel for psoriasis of the fingernails and toenails: An open, prospective study // Br J Dermatol. 2003. Vol. 149, N 1. Р. 207–209. doi: 10.1046/j.1365-2133.2003.05392.x

[127] Rigopoulos D, Ioannides D, Prastitis N, Katsambas A. Nail psoriasis: A combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol. 2002;82(2):140. doi: 10.1080/00015550252948220

[128] Rigopoulos D., Ioannides D., Prastitis N., Katsambas A. Nail psoriasis: A combined treatment using calcipotriol cream and clobetasol propionate cream // Acta Derm Venereol. 2002. Vol. 82, N 2. Р. 140. doi: 10.1080/00015550252948220

[129] Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: A dou-ble-blind, randomized, vehicle-controlled study. Cutis. 2001;68(5):355–358.

[130] Scher R.K., Stiller M., Zhu Y.I. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: A dou-ble-blind, randomized, vehicle-controlled study // Cutis. 2001. Vol. 68, N 5. Р. 355–358.

[131] Baran R, Tosti A. Topical treatment of nail psoriasis with a new corticoid-containing nail lacquer formulation. J Dermatol Treatment. 1999;10(3):201–204.

[132] Baran R., Tosti A. Topical treatment of nail psoriasis with a new corticoid-containing nail lacquer formulation // J Dermatol Treatment. 1999. Vol. 10, N 3. Р. 201–204.

[133] Tosti A, Piraccini BM, Cameli N, et al. Calcipotriol ointment in nail psoriasis: A controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol. 1998;139(4):655–659. doi: 10.1046/j.1365-2133.1998.02462.x

[134] Tosti A., Piraccini B.M., Cameli N., et al. Calcipotriol ointment in nail psoriasis: A controlled double-blind comparison with betamethasone dipropionate and salicylic acid // Br J Dermatol. 1998. Vol. 139, N 4. Р. 655–659. doi: 10.1046/j.1365-2133.1998.02462.x

[135] Yamamoto T, Katayama I, Nishioka K. Topical anthralin therapy for refractory nail psoriasis. J Dermatol. 1998;25(4):231–233. doi: 10.1111/j.1346-8138.1998.tb02386.x

[136] Yamamoto T., Katayama I., Nishioka K. Topical anthralin therapy for refractory nail psoriasis // J Dermatol. 1998. Vol. 25, N 4. Р. 231–233. doi: 10.1111/j.1346-8138.1998.tb02386.x

[137] Fredriksson T. Topically applied fluorouracil in the treatment of psoriatic nails. Arch Dermatol. 1974;110(5):735–736.

[138] Fredriksson T. Topically applied fluorouracil in the treatment of psoriatic nails // Arch Dermatol. 1974. Vol. 110, N 5. Р. 735–736.

[139] Hadeler E, Mosca M, Hong J, et al. Nail psoriasis: A review of effective therapies and recommendations for managementet. Dermatol Ther (Heidelb). 2021;11(3):799–831. doi: 10.1007/s13555-021-00523-x

[140] Hadeler E., Mosca M., Hong J., et al. Nail psoriasis: A review of effective therapies and recommendations for managementet // Dermatol Ther (Heidelb). 2021. Vol. 11, N 3. Р. 799–831. doi: 10.1007/s13555-021-00523-x

[141] Piraccini BM, Tosti A, Iorizzo M, Misciali C. Pustular psoriasis of the nails: Treatment and long-term follow-up of 46 patients. Br J Dermatol. 2001;144(5):1000–1005. doi: 10.1046/j.1365-2133.2001.04189.x

[142] Piraccini B.M., Tosti A., Iorizzo M., Misciali C. Pustular psoriasis of the nails: Treatment and long-term follow-up of 46 patients // Br J Dermatol. 2001. Vol. 144, N 5. Р. 1000–1005. doi: 10.1046/j.1365-2133.2001.04189.x

[143] De Berker D. Management of nail psoriasis. Clin Exp Dermatol. 2000;25(5):357–362. doi: 10.1046/j.1365-2230.2000.00663.x

[144] De Berker D. Management of nail psoriasis // Clin Exp Dermatol. 2000. Vol. 25, N 5. Р. 357–362. doi: 10.1046/j.1365-2230.2000.00663.x

[145] Bedi TR. Intradermal triamcinolone treatment of psoriatic onychodystrophy. Dermatologica. 1977;155(1):24–27. doi: 10.1159/000250951

[146] Bedi T.R. Intradermal triamcinolone treatment of psoriatic onychodystrophy // Dermatologica. 1977. Vol. 155, N 1. Р. 24–27. doi: 10.1159/000250951

[147] Zakeri M, Valikhani M, Mortazavi H, Barzegari M. Topical calcipotriol therapy in nail psoriasis: A study of 24 cases. Dermatol Online J. 2005;11(3):5.

[148] Zakeri M., Valikhani M., Mortazavi H., Barzegari M. Topical calcipotriol therapy in nail psoriasis: A study of 24 cases // Dermatol Online J. 2005. Vol. 11, N 3. Р. 5.

[149] Fritz K. [Successful local treatment of nail psoriasis with 5-fluorouracil. (In German)]. Z Hautkr. 1989;64(12):1083–1088.

[150] Fritz K. [Successful local treatment of nail psoriasis with 5-fluorouracil. (In German)] // Z Hautkr. 1989. Vol. 64, N 12. Р. 1083–1088.

[151] McDermott L, Madan R, Rupani R, Siegel D. A review of indigo naturalis as an alternative treatment for nail psoriasis. J Drugs Dermatol. 2016;15(3):319–323.

[152] McDermott L., Madan R., Rupani R., Siegel D. A review of indigo naturalis as an alternative treatment for nail psoriasis // J Drugs Dermatol. 2016. Vol. 15, N 3. Р. 319–323.

[153] Yew YW, Phuan CZ, Zhao X, et al. Novel transdermal device for delivery of triamcinolone for nail psoriasis treatment. Ann Acad Med Singap. 2022;51(1):16–23. doi: 10.47102/annals-acadmedsg.2021380

[154] Yew Y.W., Phuan C.Z., Zhao X., et al. Novel transdermal device for delivery of triamcinolone for nail psoriasis treatment // Ann Acad Med Singap. 2022. Vol. 51, N 1. Р. 16–23. doi: 10.47102/annals-acadmedsg.2021380

[155] Reich K, Nestle FO, Papp K, et al. EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367–1374. doi: 10.1016/S0140-6736(05)67566-6

[156] Reich K., Nestle F.O., Papp K., et al. EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial // Lancet. 2005. Vol. 366, N 9494. Р. 1367–1374. doi: 10.1016/S0140-6736(05)67566-6

[157] Reich K, Sullivan J, Arenberger P, et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol. 2019;181(5):954–966. doi: 10.1111/bjd.17351

[158] Reich K., Sullivan J., Arenberger P., et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial // Br J Dermatol. 2019. Vol. 181, N 5. Р. 954–966. doi: 10.1111/bjd.17351

[159] Huang IH, Wu PC, Yang TH, et al. Small molecule inhibitors and biologics in treating nail psoriasis: A systematic review and network meta-analysis. J Am Acad Dermatol. 2021;85(1):135–143. doi: 10.1016/j.jaad.2021.01.024

[160] Huang I.H., Wu P.C., Yang T.H., et al. Small molecule inhibitors and biologics in treating nail psoriasis: A systematic review and network meta-analysis // J Am Acad Dermatol. 2021. Vol. 85, N 1. Р. 135–143. doi: 10.1016/j.jaad.2021.01.024

[161] Reich K, Conrad C, Kristensen LE, et al. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. J Dermatolog Treat. 2022;33(3):1652–1660. doi: 10.1080/09546634.2021.1892024

[162] Reich K., Conrad C., Kristensen L.E., et al. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis // J Dermatolog Treat. 2022. Vol. 33, N 3. Р. 1652–1660. doi: 10.1080/09546634.2021.1892024

[163] Szebényi J, Gede N, Hegyi P, et al. Efficacy of biologics targeting tumour necrosis factor-alpha, interleukin-17, -12/23, -23 and small molecules targeting jak and pde4 in the treatment of nail psoriasis: A network meta-analysis. Acta Derm Venereol. 2020;100(18):adv00318. doi: 10.2340/00015555-3640

[164] Szebényi J., Gede N., Hegyi P., et al. Efficacy of biologics targeting tumour necrosis factor-alpha, interleukin-17, -12/23, -23 and small molecules targeting jak and pde4 in the treatment of nail psoriasis: A network meta-analysis // Acta Derm Venereol. 2020. Vol. 100, N 18. Р. adv00318. doi: 10.2340/00015555-3640

[165] Cassetty CT, Alexis AF, Shupack JL, Strober BE. Alefacept in the treatment of psoriatic nail disease: A small case series. J Am Acad Dermatol. 2005;52(6):1101–1102. doi: 10.1016/j.jaad.2005.01.101

[166] Cassetty C.T., Alexis A.F., Shupack J.L., Strober B.E. Alefacept in the treatment of psoriatic nail disease: A small case series // J Am Acad Dermatol. 2005. Vol. 52, N 6. Р. 1101–1102. doi: 10.1016/j.jaad.2005.01.101

[167] Körver JE, Langewouters AM, van De Kerkhof PC, Pasch MC. Therapeutic effects of a 12-week course of alefacept on nail psoriasis. J Eur Acad Dermatol Venereol. 2006;20(10):1252–1255. doi: 10.1111/j.1468-3083.2006.01783.x

[168] Körver J.E., Langewouters A.M., van De Kerkhof P.C., Pasch M.C. Therapeutic effects of a 12-week course of alefacept on nail psoriasis // J Eur Acad Dermatol Venereol. 2006. Vol. 20, N 10. Р. 1252–1255. doi: 10.1111/j.1468-3083.2006.01783.x

[169] Marx JL, Scher RK. Response of psoriatic nails to oral photochemotherapy. Arch Dermatol. 1980;116(9):1023–1024.

[170] Marx J.L., Scher R.K. Response of psoriatic nails to oral photochemotherapy // Arch Dermatol. 1980. Vol. 116, N 9. Р. 1023–1024.

[171] Alawi MA, Molochkov AV, Kulikova NG. Physiotherapeutic complex for the treatment of patients with psoriatic onychodystrophy. Acta Biomed [Internet]. 2023;94(2):e2023137.

[172] Alawi M.A., Molochkov A.V., Kulikova N.G. Physiotherapeutic complex for the treatment of patients with psoriatic onychodystrophy // Acta Biomed [интернет]. 2023. Vol. 94, N 2. Р. e2023137.

[173] Baranova U.A. Efficiency of treatment of psoriatic onychodystrophy by method of local photochemotherapy exposure. Vestnik SurGU. Meditsina. 2019;(3):51–56. (In Russ).

[174] Баранова У.А. Эффективность лечения псориатических ониходистрофий методом воздействия локальной фотохимиотерапии // Вестник СурГУ. Медицина. 2019. № 3. С. 51–56.

RIGHTS & PERMISSIONS

Eco-Vector